Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Bayer
Pfizer
Pfizer
Tizona Therapeutics, Inc
Boehringer Ingelheim
Genentech, Inc.
MacroGenics
City of Hope Medical Center
Pfizer
AbbVie
AgonOx, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
OncoNano Medicine, Inc.
Compass Therapeutics
Memorial Sloan Kettering Cancer Center
NeoTX Therapeutics Ltd.
LG Chem
West China Hospital
HiFiBiO Therapeutics
HiFiBiO Therapeutics
M.D. Anderson Cancer Center
Pfizer
Asher Biotherapeutics, Inc.
Novartis
TILT Biotherapeutics Ltd.
Providence Health & Services
Eli Lilly and Company
Thomas Jefferson University
Scholar Rock, Inc.
Tvardi Therapeutics, Incorporated
The Methodist Hospital Research Institute
Turnstone Biologics, Corp.
Seagen Inc.
Sotio Biotech Inc.
Astellas Pharma Inc
Molecular Templates, Inc.
invoX Pharma Limited
Inhibrx Biosciences, Inc
NGM Biopharmaceuticals, Inc
RemeGen Co., Ltd.
NantBioScience, Inc.
Xencor, Inc.
Gene Surgery LLC
NGM Biopharmaceuticals, Inc
University of California, San Francisco
R-Pharm
Eisai Inc.